The US Food and Drug Administration (FDA) has granted Pfizer’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate a priority review for the prevention of pneumococcal disease.
An Indian immunisation programme will make use of Pfizer’s 13-valent Pneumococcal Conjugate Vaccine (PCV 13) to treat around 5.15 million, or 20%, of the country’s at-risk infants in an attempt to neutralise the effects of one of India’s biggest killers o